according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
5.1	28.09.2024	6100581-00017	Date of first issue: 30.06.2020

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier Trade name	:	Ivermectin Formulation
1.2	Relevant identified uses of the	ne s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture	:	Veterinary product
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	MSD
			Kilsheelan Clonmel Tipperary, IE
	Telephone	:	353-51-601000
	E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Specific target organ toxicity - single exposure, Category 2	H371: May cause damage to organs.
Specific target organ toxicity - repeated exposure, Category 2	H373: May cause damage to organs through pro- longed or repeated exposure.
Short-term (acute) aquatic hazard, Cate- gory 1	H400: Very toxic to aquatic life.
Long-term (chronic) aquatic hazard, Cat- egory 1	H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)



according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Ivermectin Formulation

Versi 5.1	ion	Revision Date: 28.09.2024	-	DS Number: 100581-00017	Date of last issue: 06.07.2024 Date of first issue: 30.06.2020
I	Hazaro	l pictograms	:		
:	Signal	word	:	Warning	•
I	Hazaro	l statements	:	H371 H373	May cause damage to organs. May cause damage to organs through prolonged or repeated exposure.
				H410	Very toxic to aquatic life with long lasting effects.
I	Precau	tionary statements	:	Prevention: P264	Wash skin thoroughly after handling.
				P270	Do not eat, drink or smoke when using this prod- uct.
					Avoid release to the environment.
				Response:	
				P308 + P311	1 IF exposed or concerned: Call a POISON CENTER/ doctor.
				P391	Collect spillage.
				Storage:	
				P405	Store locked up.

Hazardous components which must be listed on the label:

Ivermectin

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No.	Classification	Concentration (% w/w)
	Index-No.		
	Registration number		
Ivermectin	70288-86-7	Acute Tox. 2; H300	>= 1 - < 2.5



according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Ivermectin Formulation

Version 5.1	Revision Date: 28.09.2024	SDS Number: 6100581-00017	Date of last issue: 06.07.2024 Date of first issue: 30.06.2020	
		274-536-0	Acute Tox. 3; H311 STOT SE 1; H370 (Central nervous system) STOT RE 1; H372 (Central nervous system) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 10,000 M-Factor (Chronic aquatic toxicity): 10,000	
2,6-D	Di-tert-butyl-p-cresol	128-37-0 204-881-4	Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 1	1

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	Wash with water and soap as a precaution. Get medical attention if symptoms occur.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.



Ivermectin Formulation

Version 5.1	Revision Date: 28.09.2024		8 Number: 0581-00017	Date of last issue: 06.07.2024 Date of first issue: 30.06.2020
lf swa	allowed	9 (so by medical pe Get medical atter Rinse mouth thor	
4.2 Most i	mportant symptoms a	nd eff	ects, both acut	e and delayed
Risks		I	May cause dama May cause dama exposure.	ge to organs. ge to organs through prolonged or repeated
4.3 Indica	tion of any immediate	medi	cal attention and	d special treatment needed
Treat	ment	: -	Freat symptomat	ically and supportively.
SECTION	1 5: Firefighting meas	sures	5	
5.1 Exting	uishing media			
-	ble extinguishing media	/	Water spray Alcohol-resistant Carbon dioxide ((Dry chemical	
Unsui media	itable extinguishing a	: 1	None known.	
5.2 Specia	al hazards arising from	the s	substance or mi	xture
Speci fightir		: 1	Exposure to com	bustion products may be a hazard to health.
Haza ucts	rdous combustion prod-	: (Carbon oxides	
5.3 Advice	e for firefighters			
	al protective equipment efighters			e, wear self-contained breathing apparatus. tective equipment.
Speci ods	fic extinguishing meth-	0 	cumstances and Jse water spray	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. ged containers from fire area if it is safe to do
		1	_vacuale alea.	

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

- Personal precautions
- : Use personal protective equipment.



Ivermectin Formulation

Version 5.1	Revision Date: 28.09.2024	SDS Number: 6100581-00017	Date of last issue: 06.07.2024 Date of first issue: 30.06.2020		
			andling advice (see section 7) and personal pro- nent recommendations (see section 8).		
6.2 Enviro	nmental precautions				
Enviro	nmental precautions	Prevent furthe Prevent sprea barriers). Retain and dis Local authoriti	Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil		
6.3 Method	Is and material for co	ontainment and cle	aning up		
Metho	ds for cleaning up	For large spills ment to keep to be pumped, si Clean up rema bent. Local or nation posal of this m employed in th mine which re Sections 13 an	nert absorbent material. s, provide dyking or other appropriate contain- material from spreading. If dyked material can core recovered material in appropriate container. aining materials from spill with suitable absor- nal regulations may apply to releases and dis- naterial, as well as those materials and items ne cleanup of releases. You will need to deter- gulations are applicable. Ind 15 of this SDS provide information regarding r national requirements.		

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	: Use only with adequate ventilation.
Advice on safe handling	: Do not breathe mist or vapours.
	Do not swallow.
	Avoid contact with eyes.
	Avoid prolonged or repeated contact with skin.
	Wash skin thoroughly after handling.
	Handle in accordance with good industrial hygiene and safety
	practice, based on the results of the workplace exposure as- sessment
	Do not eat, drink or smoke when using this product.
	Take care to prevent spills, waste and minimize release to the
	environment.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye
	flushing systems and safety showers close to the working
	place. When using do not eat, drink or smoke. Wash contami-
	nated clothing before re-use.
	-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Ivermectin Formulation

Version 5.1	Revision Date: 28.09.2024	SDS Ni 610058	ımber: 1-00017	Date of last issue: 06.07.2024 Date of first issue: 30.06.2020
		eng app indu	ineering contr ropriate dego istrial hygiene	eration of a facility should include review of rols, proper personal protective equipment, wning and decontamination procedures, e monitoring, medical surveillance and the tive controls.
7.2 Cond	itions for safe storage,	includin	g any incom	patibilities
•	Requirements for storage areas and containers			labelled containers. Store locked up. Store in the particular national regulations.
Advi	ce on common storage	Stro Self Org	ng oxidizing -reactive sub anic peroxide losives	stances and mixtures
7.3 Spec	ific end use(s)			
•	cific use(s)	: No o	data available	9

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis	
Ivermectin	70288-86-7	TWA	30 µg/m3 (OEB 3)	Internal	
	Further information: Skin				
		Wipe limit	300 µg/100 cm2	Internal	
2,6-Di-tert-butyl-p-	128-37-0	OELV - 8 hrs	2 mg/m3	IE OEL	
cresol		(TWA)			

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
2,6-Di-tert-butyl-p- cresol	Workers	Inhalation	Long-term systemic effects	3.5 mg/m3
	Workers	Dermal	Long-term systemic effects	0.5 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	0.86 mg/m3
	Consumers	Dermal	Long-term systemic effects	0.25 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	0.25 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
2,6-Di-tert-butyl-p-cresol	Fresh water	0.199 µg/l

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Ivermectin Formulation

Version 5.1	Revision Date: 28.09.2024	SDS Number: 6100581-00017	Date of last issue: 0 Date of first issue: 3		
		Intermittent us	e/release	0.02 µg/l	
		Marine water		0.02 µg/l	
		Sewage treatr	nent plant	0.17 mg/l	
		Fresh water se	ediment	0.0996 mg/kg dry weight (d.w.)	
		Marine sedime	ent	0.00996 mg/kg dry weight (d.w.)	
		Soil	Soil		
		Oral (Seconda	ary Poisoning)	8.33 mg/kg food	

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection : Hand protection	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Material :	Chemical-resistant gloves
	Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis- posable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection : Filter type :	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143 Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	 :	oily
Colour	:	light yellow

7/22

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Ivermectin Formulation

Vers 5.1	sion	Revision Date: 28.09.2024		S Number: 0581-00017	Date of last issue: 06.07.2024 Date of first issue: 30.06.2020
	Odour		:	characteristic	
	Odour ⁻	Threshold	:	No data available	
	Melting	point/freezing point	:	No data available	
Initial boiling point and boiling range		:	167.5 °C		
	Flamma	ability (solid, gas)	:	Not applicable	
	Flamma	ability (liquids)	:	No data available	
		explosion limit / Upper bility limit	:	No data available	
		explosion limit / Lower bility limit	:	No data available	
	Flash p	oint	:	219.2 °C	
	Auto-ig	nition temperature	:	No data available	
	Decom	position temperature	:	No data available	
	рН		:	No data available	
	Viscosi Visc	ty cosity, kinematic	:	No data available	
	Solubili Wat	ty(ies) er solubility	:	practically insolut	ble
	Partitio octanol	n coefficient: n- /water	:	Not applicable	
	Vapour	pressure	:	No data available	
	Relative	e density	:	0.88 - 0.92	
	Density	,	:	No data available	
	Relative	e vapour density	:	No data available	
		characteristics icle size	:	Not applicable	

9.2 Other information



Ivermectin Formulation

Version 5.1	Revision Date: 28.09.2024		OS Number: 00581-00017	Date of last issue: 06.07.2024 Date of first issue: 30.06.2020		
Explo	sives	:	Not explosive			
Oxidizing properties		:	: The substance or mixture is not classified as oxidizing.			
Evaporation rate :			No data availabl	e		
Moleo	cular weight	:	No data availabl	e		

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

-		
Hazardous reactions	:	Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid	: Oxidizing agent	S
--------------------	-------------------	---

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of	:	Inhalation
exposure		Skin contact
		Ingestion
		Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
Acute dermal toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method

Components:

Ivermectin:

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



ersion 1	Revision Date: 28.09.2024	-	DS Number: 00581-00017	Date of last issue: 06.07.2024 Date of first issue: 30.06.2020	
Acute	oral toxicity	:	LD50 (Rat): 50 n	ng/kg	
			LD50 (Mouse): 2	5 mg/kg	
			Symptoms: Vom	> 24 mg/kg Central nervous system iting, Dilatation of the pupil ortality observed at this dose.	
Acute	inhalation toxicity	:	: LC50 (Rat): 5.11 mg/l Exposure time: 1 h Test atmosphere: dust/mist		
Acute	e dermal toxicity	:	LD50 (Rabbit): 4	06 mg/kg	
			LD50 (Rat): > 66	0 mg/kg	
2,6-D	i-tert-butyl-p-cresol:				
Acute	e oral toxicity	:	LD50 (Rat): > 6,0 Method: OECD	000 mg/kg Fest Guideline 401	
Acute	e dermal toxicity	:		000 mg/kg Fest Guideline 402 e substance or mixture has no acute dermal	
Skin	corrosion/irritation				
	lassified based on avai	lable	information.		
<u>Comp</u>	oonents:				
	nectin:				
Speci Resul		:	Rabbit No skin irritation		
2,6-D	i-tert-butyl-p-cresol:				
Speci		:	Rabbit		
Metho Resul		:	OECD Test Guid No skin irritation	leline 404	
Rema		:		om similar materials	
	us eye damage/eye ir				
Not cl	lassified based on avai	lable	information.		
<u>Comp</u>	oonents:				
-	nectin:				
Speci Resul		:	Rabbit Mild eye irritatior	1	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
5.1	28.09.2024	6100581-00017	Date of first issue: 30.06.2020

2,6-Di-tert-butyl-p-cresol:

Species :	Rabbit
Method :	OECD Test Guideline 405
Result :	No eye irritation
Remarks :	Based on data from similar materials

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Ivermectin:

Exposure routes	:	Dermal
Species	:	Humans
Result	:	Does not cause skin sensitisation.

2,6-Di-tert-butyl-p-cresol:

Test Type	:	Human repeat insult patch test (HRIPT)
Exposure routes	:	Skin contact
Species	:	Humans
Result	:	negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Ivermectin: Test Type: Bacterial reverse mutation assay (AMES) Genotoxicity in vitro : **Result:** negative Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Test system: human diploid fibroblasts **Result:** negative Test Type: Mouse Lymphoma Result: negative 2,6-Di-tert-butyl-p-cresol: Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) **Result:** negative Test Type: In vitro mammalian cell gene mutation test **Result:** negative

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



ersion I	Revision Date: 28.09.2024		OS Number: 00581-00017	Date of last issue: 06.07.2024 Date of first issue: 30.06.2020
			Test Type: Chro Result: negative	pmosome aberration test in vitro
Genot	toxicity in vivo	:		
	nogenicity			
	assified based on ava	ailable	information.	
<u>Comp</u>	oonents:			
lverm	ectin:			
Speci		:	Rat	
Applic NOAE	ation Route	:	Oral	weight
Resul		÷	1.5 mg/kg body negative	weight
Rema	irks	:		rom similar materials
Speci		:	Mouse	
	ation Route	:	Oral	
NOAE Resul		:	2.0 mg/kg body negative	weight
Rema		:		rom similar materials
2,6-Di	i-tert-butyl-p-cresol:			
Speci		:	Rat	
Applic	ation Route	:	Ingestion	
Expos Resul	sure time	:	22 Months	
Resul	L	•	negative	
•	oductive toxicity			
	assified based on ava	ailable	information.	
	oonents:			
-	ectin:		Toot Turner Fart	1:4.7
Ellect	s on fertility	-	Test Type: Ferti Species: Rat	шу
			Application Rou	te: Oral
				.: 0.6 mg/kg body weight
			Result: Animal f	esting did not show any effects on fertility.
	s on foetal develop-	:	Test Type: Dev	
ment			Species: Mouse	
			Application Rou Developmental	te: Orai Toxicity: NOAEL: 0.2 mg/kg body weight
			Result: Teratog	enic effects, Embryotoxic effects and adverse
			effects on the o	ffspring were detected only at high maternally
			toxic doses	hopining word dottotted only at high materially

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Version 5.1	Revision Date: 28.09.2024		DS Number: 00581-00017	Date of last issue: 06.07.2024 Date of first issue: 30.06.2020
			Result: Embryoto spring were dete	e: Oral Toxicity: LOAEL: 0.4 mg/kg body weight pxic effects and adverse effects on the off-
2.6-D	i-tert-butyl-p-cresol:			
	s on fertility	:	Test Type: Two- Species: Rat Application Rout Result: negative	generation reproduction toxicity study e: Ingestion
Effect ment	s on foetal develop-	:	Test Type: Embr Species: Rat Application Rout Result: negative	yo-foetal development e: Ingestion
	- single exposure cause damage to organs	s.		
	oonents:			
lverm	nectin:			
	et Organs ssment	:	Central nervous Causes damage	
	- repeated exposure cause damage to organs	s thi	ough prolonged or	r repeated exposure.
<u>Com</u>	oonents:			
lverm	nectin:			
	et Organs ssment	:	Central nervous Causes damage exposure.	system to organs through prolonged or repeated
2,6-D	i-tert-butyl-p-cresol:			
	ssment	:	No significant he tions of 100 mg/ł	alth effects observed in animals at concentra- kg bw or less.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Ivermectin Formulation

Ver 5.1	sion	Revision Date: 28.09.2024		Number: 0581-00017	Date of last issue: 06.07.2024 Date of first issue: 30.06.2020
	Repea	ated dose toxicity			
	<u>Comp</u>	onents:			
	lverm	ectin:			
	Expos Target Sympt	L L ation Route ure time t Organs coms	: 0 : 1 : C : 1 : C : E		ystem upil, Tremors, Lack of coordination, anorexia
	Specie NOAE			/lonkey I.2 mg/kg	
	-	ation Route		Dral	
		ure time		2 Weeks	
	Rema	IKS	: P	No significant adv	rerse effects were reported
	Specie			Rat	
	NOAE).4 mg/kg	
		L ation Route).8 mg/kg Dral	
		ure time		3 Months	
		tOrgans		pleen, Bone mar	row, Kidney
	2,6-Di Specie NOAE			Rat 25 mg/kg	
	Applic	ation Route	: h	ngestion	
	Expos	ure time	: 2	22 Months	
11 -	Not cla	ation toxicity assified based on avail nation on other hazar		formation.	
		crine disrupting prope	erties		
	Produ				
	Asses	sment	e F (I	ered to have endo REACH Article 57	ixture does not contain components consid- ocrine disrupting properties according to (f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at higher.
	Exper	ience with human ex	osure	9	

Components:

Ivermectin:

Skin contact

: Remarks: Can be absorbed through skin.



Ver 5.1	sion	Revision Date: 28.09.2024		0S Number: 00581-00017	Date of last issue: 06.07.2024 Date of first issue: 30.06.2020		
	Eye contact Ingestion		:	Remarks: May irritate eyes. Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Von iting, anorexia, Lack of coordination			
SE	SECTION 12: Ecological information						
12.1	I Toxicit	ţ					
	Compo	onents:					
	lverme	ctin:					
	Toxicity	<i>t</i> to fish	:	LC50 (Oncorhync Exposure time: 96	hus mykiss (rainbow trout)): 0.003 mg/l i h		
				LC50 (Lepomis m Exposure time: 96	acrochirus (Bluegill sunfish)): 0.0048 mg/l i h		
		to daphnia and other invertebrates	:	EC50 (Daphnia m Exposure time: 48	agna (Water flea)): 0.000025 mg/l h		
	Toxicity plants	/ to algae/aquatic	:	EC50 (Pseudokiro mg/l Exposure time: 72 Method: OECD Te			
				NOEC (Pseudokir mg/l Exposure time: 72 Method: OECD Te			
	M-Fact icity)	or (Acute aquatic tox-	:	10,000			
	M-Fact toxicity)	or (Chronic aquatic)	:	10,000			
	2,6-Di-1	tert-butyl-p-cresol:					
	Toxicity	/ to fish	:	Exposure time: 96	(zebra fish)): > 0.57 mg/l 5 h 67/548/EEC, Annex V, C.1.		
		to daphnia and other invertebrates	:	EC50 (Daphnia m Exposure time: 48 Method: OECD Te			
	Toxicity plants	/ to algae/aquatic	:	ErC50 (Pseudokir mg/l Exposure time: 72 Method: OECD Te			
				NOEC (Pseudokir mg/l Exposure time: 72	chneriella subcapitata (green algae)): 0.24 [.] h		



Version 5.1	Revision Date: 28.09.2024		DS Number: Date of last issue: 06.07.2024 100581-00017 Date of first issue: 30.06.2020
			Method: OECD Test Guideline 201
M-F icity	Factor (Acute aquatic tox- /)	:	1
To>	kicity to microorganisms	:	EC50 : > 10,000 mg/l Exposure time: 3 h Method: OECD Test Guideline 209
To> icity	<pre>kicity to fish (Chronic tox- /)</pre>	:	NOEC: 0.053 mg/l Exposure time: 30 d Species: Oryzias latipes (Japanese medaka) Method: OECD Test Guideline 210
aqu	kicity to daphnia and other uatic invertebrates (Chron- oxicity)	:	NOEC: 0.316 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea)
	Factor (Chronic aquatic icity)	:	1
12.2 Pe	rsistence and degradabil	ity	
Co	mponents:		
lve	rmectin:		
Bio	degradability	:	Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 240 d
2,6	-Di-tert-butyl-p-cresol:		
	degradability	:	Result: Not readily biodegradable. Biodegradation: 4.5 % Exposure time: 28 d Method: OECD Test Guideline 301C
12.3 Bio	baccumulative potential		
<u>Co</u>	mponents:		
-	rmectin:		
Bio	accumulation	:	Bioconcentration factor (BCF): 74
	tition coefficient: n- anol/water	:	log Pow: 3.22
	-Di-tert-butyl-p-cresol:		
Bio	accumulation	:	Species: Cyprinus carpio (Carp) Bioconcentration factor (BCF): 330 - 1,800
	tition coefficient: n- anol/water	:	log Pow: 5.1



Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
5.1	28.09.2024	6100581-00017	Date of first issue: 30.06.2020

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment

: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:	
Assessment	: The substance/mixture does not contain components consid- ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	 Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number		
ADN	:	UN 3082
ADR	:	UN 3082
RID	:	UN 3082
IMDG	:	UN 3082
ΙΑΤΑ	:	UN 3082

14.2 UN proper shipping name

: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.



Versio 5.1	on	Revision Date: 28.09.2024		9S Number: 00581-00017	Date of last issue: 06.07.2024 Date of first issue: 30.06.2020
				(Ivermectin, 2,6-D	Di-tert-butyl-p-cresol)
А	ADR		:	N.O.S.	ALLY HAZARDOUS SUBSTANCE, LIQUID, Di-tert-butyl-p-cresol)
R	RID		:	ENVIRONMENTA N.O.S.	ALLY HAZARDOUS SUBSTANCE, LIQUID,
II	MDG		:	ENVIRONMENTA N.O.S.	ALLY HAZARDOUS SUBSTANCE, LIQUID,
14	ΑΤΑ		:	Environmentally h	nazardous substance, liquid, n.o.s. Di-tert-butyl-p-cresol)
14.3 T	Fransp	oort hazard class(es)			
				Class	Subsidiary risks
Α	DN		:	9	
Α	DR		:	9	
R	RID		:	9	
I	MDG		:	9	
I/	ΑΤΑ		:	9	
14.4 P	Packin	ng group			
P C H	Classifi	g group ication Code I Identification Number	: :	III M6 90 9	
P C H L	Classifi Iazard .abels	g group ication Code I Identification Number restriction code	: : : : : : : : : : : : : : : : : : : :	III M6 90 9 (-)	
P C H	Classifi	g group ication Code I Identification Number	:	III M6 90 9	
P L	MDG Packing abels EmS C	g group ode	:	III 9 F-A, S-F	
P a	Packin ircraft		:	964	
Р	Packin	g instruction (LQ)	:	Y964	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Ivermectin Formulation

Versi 5.1	ion	Revision Date: 28.09.2024		OS Number: 00581-00017	Date of last issue: 06.07.2024 Date of first issue: 30.06.2020
	Packing Labels	g group	:	III Miscellaneous	
		Passenger) g instruction (passen- craft)	:	964	
	Packing	g instruction (LQ) g group	:	Y964 III Miscellaneous	
		nmental hazards			
	ADN Enviror	nmentally hazardous	:	yes	
	ADR Enviror	nmentally hazardous	:	yes	
	RID Enviror	mentally hazardous	:	yes	
	IMDG Marine	pollutant	:	yes	
		Passenger) nmentally hazardous	:	yes	
	IATA (Enviror	Cargo) Imentally hazardous	:	yes	
146	Snecia	I precautions for use	r		

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks

: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Conditions of restriction for the following entries should be considered: Number on list 3

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is appli-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Ivermectin Formulation

Version 5.1	Revision Date: 28.09.2024	SDS Number: 6100581-00017		of last issue: 06.07.2024 of first issue: 30.06.2020
				cable to the placing on the market or
				not.
	ACH - Candidate List of cern for Authorisation (jh :	Not applicable
	ulation (EC) on substar	,	one :	Not applicable
Reg	ulation (EU) 2019/1021 s (recast)	on persistent organic p	ollu- :	Not applicable
Reg mer	ulation (EU) No 649/20 at and the Council conce angerous chemicals			Not applicable
REA	ACH - List of substances nex XIV)	s subject to authorisatio	n :	Not applicable
Šev	,	-		nt and of the Council on the control of
,		5 5		Quantity 1 Quantity 2

		Quantity 1	Quantity 2
E1	ENVIRONMENTAL	100 t	200 t
	HAZARDS		

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H300	:	Fatal if swallowed.
H311	:	Toxic in contact with skin.
H370	:	Causes damage to organs if swallowed.
H372	:	Causes damage to organs through prolonged or repeated exposure if swallowed.
H400	:	Very toxic to aquatic life.
H410	:	Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations



Ivermectin Formulation

Versi 5.1	on Revision Date: 28.09.2024	SDS Number: 6100581-00017	Date of last issue: 06.07.2024 Date of first issue: 30.06.2020
	Acute Tox. Aquatic Acute Aquatic Chronic STOT RE STOT SE E OEL	 Long-term (ch Specific target Specific target Ireland. List of pational Expositional Expositiona	cute) aquatic hazard ronic) aquatic hazard corgan toxicity - repeated exposure corgan toxicity - single exposure Chemical Agents and Carcinogens with Occu- sure Limit Values - Code of Practice, Schedule 1
	E OEL / OELV - 8 hrs (TWA)	and 2 : Occupational	exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration: NO(A)EL - No Observed (Adverse) Effect Level: NOELR - No Observable Effect Loading Rate: NZIOC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to : compile the Safety Data	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-
Sheet	cy, http://echa.europa.eu/

Classification of the mixture:		Classification procedure:
STOT SE 2	H371	Calculation method
STOT RE 2	H373	Calculation method



Ivermectin Formulation

Version 5.1	Revision Date: 28.09.2024	SDS Number: 6100581-00017	Date of last issue: 06.07.2024 Date of first issue: 30.06.2020	
Aqua	tic Acute 1	H400	Calculation method	
Aqua	tic Chronic 1	H410	Calculation method	

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN